If I do not get a call for a scheduled peer to peer, it should be an automatic medication approval, not a game of rescheduling or deadlines. Your failures and hoop jumping should not be my or my patients’ problem!! @medmutual#IBD#crohnsandcolitis#insurance
The American College of Obstetricians and Gynecologists has made the decision to forego federal funding in order to maintain the integrity of their evidence-based work on maternal health, preventive care, and more.
Find out more in a new letter: https://t.co/vX4Gor0clH
The FDA has approved TREMFYA® (guselkumab) for fully subcutaneous induction in adults with ulcerative colitis — making it the first and only IL-23 inhibitor with a complete SC regimen. 💉✅
🔹 Why this matters:
🌸 Convenience: No IV required — patients can start therapy at home.
🌸 Flexibility: Choice of SC or IV induction supports shared decision-making.
🌸 Access & Capacity: Less strain on infusion centers, more independence for patients.
🌸 Consistency: Strong clinical outcomes with early symptom improvement as soon as week 2 and sustained through week 24.
This milestone expands treatment options and represents another step forward in patient-centered IBD care.
https://t.co/QYx7zZdg8U
Many surprises in this @AGA_CGH meta analysis
JAKi no better than placebo for ileal disease
Stronger effect of Vedo for ileal than for colonic disease
A progress towards positioning in #IBD
Will patients with refractory ileocolonic disease benefit from a JAKi+Vedo combo?
🔬 JAKing up the options for perianal fistulas in Crohn’s disease!
New post hoc analysis from 3 phase 3 trials (U-EXCEL, U-EXCEED, U-ENDURE) shows promising results for upadacitinib in patients with perianal fistulizing CD:
✅ 44.7% of patients on upadacitinib 45mg QD had resolution of drainage at 12 weeks vs 5.6% placebo (p=0.003)
✅ 22.1% had closure of external openings vs 4.8% placebo (p=0.013)
✅ Sustained benefit into 52-week maintenance with both 15mg and 30mg doses
✅ No new safety signals identified
🧠 These findings offer new hope for a tough-to-treat phenotype, especially in biologic-experienced patients.
Paper published in @AGA_CGH by @JeanFredericCo1@RPanaccione@IBD_FloMD and others
📌 Further studies needed to confirm long-term healing with imaging.
https://t.co/cEeagLCb5c
IBD/IBS overlap is common and challenging. Here is a practical guide for the evaluation and diagnosis led by @GIJANE_MD
https://t.co/xdiefz684s
#IBSawarenessmonth
Thought I was doing a peer to peer with a true peer…but the pediatric gastroenterologist on the line did not even know what induction dosing of infliximab was😡 #insurance#medicalmutual#pedsgi#IBD
🌟 𝗡𝘂𝗺𝗯𝗲𝗿 𝟭𝟬🌟
Implementing a standardized protocol for steroid weaning in pediatric #IBD patients led to a significant reduction in #steroid use without increasing flares or hospitalizations. #Pediatrics#QI
https://t.co/61ZjK2iYWe
NEW STUDY: HOW DOES MILD IBD PROGRESS OVER TIME?
Read our new study in Clinical Gastroenterology and Hepatology, focusing on the often-overlooked subgroup of patients with mild IBD ➡️ https://t.co/tFTcRXEPqW
A study funded by the CDC was just published which indicates the prevalence of pediatric IBD in the US is among the highest worldwide with an estimated 100,429 Americans under the age of 20 currently living with #IBD.
https://t.co/FdcQPaAk2P
🔄 New @ESPGHANSociety@NASPGHAN 2023 guidelines on pediatric #Hpylori management emphasize invasive testing & strain susceptibility for treatment. Noninvasive tests for high-risk kids & avoiding clarithromycin are recommended. #pediatrics#cme
https://t.co/YtCWaRtdeO
Implementing a standardized protocol for steroid weaning in pediatric #IBD patients led to a significant reduction in #steroid use without increasing flares or hospitalizations. #Pediatrics#QI
https://t.co/61ZjK2iYWe